Table 1 Demographic and clinical characteristics of study groups
From: lincR-Ccr2-5′AS and THRIL as potential biomarkers of multiple sclerosis
MS patients (n=74) | Control (n=60) | p-value | |
|---|---|---|---|
Age [years] mean ±SD | 32.5±8.1 | 30.2±9.2 | 0.13 |
Sex [no. (%)] | |||
Female | 62 (83.8%) | 48 (80%) | 0.59 |
Male | 12 (16.2%) | 12 (20%) | |
Types of MS [no. (%)] | |||
RRMS | 54 (73%) | ||
SPMS | 20 (27%) | ||
Initial presentation [no. (%)] | |||
Optic neuritis | 24 (32.4%) | ||
Sensory symptoms | 10 (13.5%) | ||
Motor symptoms | 40 (54.1%) | ||
Family history of MS [no. (%)] | |||
Positive | 4 (5.4%) | 0 | |
Negative | 70 (94.6%) | 60 (100%) | |
Age of onset (years) [mean ±SD] | 25.9±7.4 | ||
EDSS score [mean ±SD] | 3.4±1.9 | ||
EDSS = 1–3 | 42 (56.8%) | ||
EDSS = 3.5–5 | 14 (18.9%) | ||
EDSS ≥ 5.5 | 18 (24.3%) | ||
Treatment [no. (%)] | |||
Treatment naive | 18 (24.3%) | ||
Interferon | 40 (54.1%) | ||
Immunosuppressants | |||
Azathioprine | 12 (16.2%) | ||
Cyclophosphamide | 4 (5.4%) | ||